ArticleNeoplasia (New York, N.Y.)2008
A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.
Article in Neoplasia (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- mRNA ratios of AR to ESR1 and PGR distinguish breast cancer subtypes based on public datasets and experimental models.Scientific reports · 2025Pooled it
- Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Clinicopathological observation and initial exploration of characteristic biomarkers in breast apocrine carcinoma.Journal of translational medicine · 2026Article
- Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.NPJ breast cancer · 2026Article
- The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?Reproductive biology and endocrinology : RB&E · 2025Review
- Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer.International journal of molecular sciences · 2024Review
- Androgen Receptor Expression in ER and PR Negative Breast Cancer-A Study from a Tertiary Hospital in Northern India.South Asian journal of cancer · 2023Article
- Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients.Journal of cancer research and clinical oncology · 2023Article
- Review
- Revisiting Androgen Receptor Signaling in Breast Cancer.The oncologist · 2023Article
- Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.Endocrinology · 2023Review
- Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far.OncoTargets and therapy · 2023Review
- Role of androgen receptor signaling pathway-related lncRNAs in the prognosis and immune infiltration of breast cancer.Scientific reports · 2022Article
- FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact.Cancers · 2022Article
- Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line.Clinical proteomics · 2022Article
- BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.Breast cancer (Tokyo, Japan) · 2022Article
- Apocrine lesions of the breast.Virchows Archiv : an international journal of pathology · 2022Review
- Androgen receptor in breast cancer: The "5W" questions.Frontiers in endocrinology · 2022Review
- Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature.BMC women's health · 2021Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have identified novel subgroups in ER-negative breast cancer based on the expression pattern of androgen receptor (AR). One subtype (molecular apocrine) has an over-expression of steroid-response genes and ErbB2. Using breast cancer cell lines with molecular apocrine features, we demonstrate a functional cross-talk between AR and ErbB2 pathways. We show that stimulation of AR and ErbB2 pathways leads to the cross-regulation of gene expression for AR, ErbB2, FOXA1, XBP1, TFF3, and KLK3. As opposed to the physiologic transient phosphorylation of extracellular signal-regulated kinase (ERK1/2) observed with the testosterone treatment, we demonstrate that the addition of ErbB2 inhibition leads to a persistent phosphorylation of ERK1/2, which negatively regulates the downstream signaling and cell growth. This suggests a mechanism for the cross-talk involving the ERK pathway. Moreover, testosterone stimulates the proliferation of molecular apocrine breast cell lines, and this effect can be reversed using antiandrogen flutamide and anti-ErbB2 AG825. Conversely, the growth stimulatory effect of heregulin can also be inhibited with flutamide, suggesting a cross-talk between the AR and ErbB2 pathways affecting cell proliferation. Importantly, there is a synergy with the combined use of flutamide and AG825 on cell proliferation and apoptosis, which indicates a therapeutic advantage in the combined blockage of AR and ErbB2 pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.